Sublingual Buprenorphine Initiation: The Traditional Method #441

Dowell D , Compton WM , and Giroir BP : Patient-centered reduction or discontinuation of long-term opioid analgesics: The HHS Guide for Clinicians. JAMA, 2019; 322:1855–1856.

Becker WC , Merlin JS , Manhapra A , and Edens EL : Management of patients with issues related to opioid safety, efficacy and/or misuse: A case series from an integrated, interdisciplinary clinic. Addict Sci Clin Pract, 2016; 11:3.

Manhapra A and Becker WC : Pain and addiction: An integrative therapeutic approach. Med Clin North Am, 2018; 102:745–763.

DeFlavio JR , Rolin SA , Nordstrom BR , and Kazal LA Jr .: Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health, 2015; 15:3019.

Buprenorphine Notice of Intent. https://buprenorphine.samhsa.gov/forms/select-practitioner-type.php (Last accessed February 10, 2022).

Department of Health and Human Services: New Buprenorphine Guidelines: 2021. https://www.samhsa.gov/newsroom/press-announcements/2021042709302021 (Last accessed February 10, 2022).

Substance Abuse and Mental Health Service Administration: Buprenorphine Quick Start Guide. https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf2021 (Last accessed February 10, 2022).

The American Society of Addiction Medicine National Practice Guidelines for the Treatment of opioid use disorder 2020 focused update. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_22021 (Last accessed February 10, 2022).

Provider Clinical Support System Medication for Opioid Use Disorder. http://pcssnow.org (Last accessed February 10, 2022).

Provider Clinical Support System Mentoring Program. https://pcssnow.org/mentoring/2020 (Last accessed February 10, 2022).

National Clinician Consultation Center. https://nccc.ucsf.edu (Last accessed February 10, 2022).

Jones KF : Buprenorphine use in palliative care. J Hosp Palliat Nurs, 2019; 21540–547.

Lee JD , Grossman E , DiRocco D , and Gourevitch MN : Home buprenorphine/naloxone induction in primary care. J Gen Intern Med, 2009; 24226–232.

Martin SA , Chiodo LM , Bosse JD , and Wilson A : The next stage of buprenorphine care for opioid use disorder. Ann Intern Med, 2018; 169:628–635.

Haffajee RL , Bohnert ASB , and Lagisetty PA : Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med, 2018; 54(6 Suppl 3):S230–s242.

Clinical Opioid Withdrawal Scale. https://www.asam.org/docs/default-source/education-docs/cows_induction_flow_sheet.pdf?sfvrsn=b577fc2_2 (Last accessed February 10, 2022).

SOWS. https://www.asam.org/docs/default-source/education-docs/sows_8-28-2017.pdf?sfvrsn=f30540c2_2 (Last accessed February 10, 2022).

Gunderson E : Models of buprenorphine induction. http://pcssnow.org/wpcontent/uploads/2015/02/Buprenorphine-Induction-Online-Module.pd2015 (Last accessed February 10, 2022).

Center for Substance Abuse SAMHSA/CSAT Treatment Improvement Protocols:. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration (US), 2004.

Gudin J and Fudin J : A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther, 2020; 9:41–54.